Back to Search
Start Over
A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma.
- Source :
-
Cancer Investigation . Mar2013, Vol. 31 Issue 3, p172-176. 5p. 4 Charts. - Publication Year :
- 2013
-
Abstract
- Purpose: This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcadeā¢) (AAV) for patients with relapsed/refractory multiple myeloma. Experimental Design: ATO (0.25 mg/kg) and AA (1 g) were given with an escalating dose of bortezomib (1 mg/m2 or 1.3 mg/m2 IV bolus on days 1 and 8 of a 21-day cycle). Results: Ten patients (median age 62 years), with a median of 3 prior regimens, were enrolled. Four (40%) patients achieved clinical benefit, with one patient achieving a durable partial response. No formal DLTs were encountered. Conclusion: AAV combination was feasible and demonstrated some benefits in this heavily pretreated population. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 07357907
- Volume :
- 31
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Cancer Investigation
- Publication Type :
- Academic Journal
- Accession number :
- 85985721
- Full Text :
- https://doi.org/10.3109/07357907.2012.756109